Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis …
This multicenter watch-and-measure (no experimental treatment required) cohort study aims to evaluate whether estimated first-trimester risk of preeclampsia (PE) is associated with subclinical atherosclerosis, cardiovascular risk profile, and cardiovascular events in women with type 1 diabetes (T1D) at least 3 years after pregnancy. Women with T1D and at least one prior pregnancy with documented first-trimester PE screening will be classified as high or low PE risk according to validated multivariable algorithms.
Official registry: https://clinicaltrials.gov/study/NCT07479329 · Institut d'Investigacions Biomèdiques August Pi i Sunyer · enrollment listed as 1,300
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 1,300 people at 2 sites. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Primary outcome (registry wording): Number of carotid plaques
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Women only
- Confirmed diagnosis of type 1 diabetes
- At least one prior pregnancy with first-trimester preeclampsia screening (\<14 weeks gestation)
- ≥3 years since last pregnancy
Who the registry excludes
- Previous multiple pregnancy
- Cardiovascular disease before pregnancy (coronary heart disease, stroke/TIA, peripheral artery disease, heart failure)
- Active pregnancy at time of evaluation
- Alcohol or substance dependence (except nicotine/caffeine) in the last 3 years
- Active severe psychiatric disease, dementia, severe disability, or reduced life expectancy
Public study contact (from the registry)
Verónica Perea, MD, PhD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
2 listed- Hospital Clínic Barcelona — Barcelona, Barcelona, Spain (recruiting)
- Hospital Universitari Mútua Terrassa — Terrassa, Terrassa, Spain (not_yet_recruiting)
FAQ about this NCT record
Is NCT07479329 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07479329?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07479329?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary